ProMIS Neurosciences

ProMIS Neurosciences P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of ProMIS Neurosciences (PMN) as of Oct 27, 2026 is -3.03. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -1.93 — a change of 57.05% (lower).

P/FCF

-3.03

YoY

57.05%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of ProMIS Neurosciences is 2023 -3.03 . P/FCF (Price-to-Free-Cash-Flow Ratio) of ProMIS Neurosciences was 2022 -1.93 . It decreases by 57.05% lower compared to the previous year.

The ProMIS Neurosciences P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2016
-17.10 USD
Jan 1, 2017
-7.48 USD
Jan 1, 2018
-4.92 USD
Jan 1, 2019
-7.15 USD
Jan 1, 2020
-9.86 USD
Jan 1, 2021
-3.52 USD
Jan 1, 2022
-1.93 USD
Jan 1, 2023
-3.03 USD
The ProMIS Neurosciences P/FCF history
YEARP/FCFYoY
-3.03+57.05%
-1.93-45.27%
-3.52-64.27%
-9.86+37.84%
-7.15+45.32%
-4.92-34.18%
-7.48-56.26%
-17.10-35.94%
-26.69+0.81%
-26.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of ProMIS Neurosciences is -3.03 in 2023.

P/FCF (Price-to-Free-Cash-Flow Ratio) of ProMIS Neurosciences changed from -1.93 to -3.03, representing a 57.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s ProMIS Neurosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — ProMIS Neurosciences

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — ProMIS Neurosciences